#Yescarta
LightNews LightNews
viriditax.bsky.social
cf Uniqure’s Huntington’s disease read-out, Trifakta and Yescarta being casual standards of care, voxelotor kicking off a reverse genetics wave (ISG15, DEC2, and SCN9A are the ones I’m watching), sustained Q > 0.5, cheap robot and compute parts, PVC-eating bacteria, cultured bacon, etc
September 27, 2025 at 3:22 AM
thestarkest.bsky.social
There is a cancer treatment on the market called YESCARTA and every time I see the name I think about @cartamonir.com!
March 27, 2025 at 5:55 PM
jdevos.bsky.social
Gilead is testing a bicistronic anti-CD19/CD20 #CAR_T made with a rapid manufacturing method in a Phase III trial vs. Yescarta. Reinventing its own game-changer less than a decade after commercialization.
Gilead puts its Car-T money where its mouth is
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
buff.ly
March 24, 2026 at 10:25 AM
danafarber.bsky.social
Dana-Farber-led research helped drive an @fda.gov label update for axicabtagene ciloleucel (Yescarta) that removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients. Learn more: bit.ly/4rjfgbU
Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma | Dana-Farber Cancer Institute
Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive lymphoma of the brain and spinal cord. The change is expected to expand access to commercial CAR T-cell therapy for eligible patients with relapsed or refractory disease.
bit.ly
February 12, 2026 at 9:42 PM
sababausa.bsky.social
the gist of this is they're reporting several case studies of off-label Yescarta treating patients with very severe presentations of certain autoimmune disorders (a few of the authors work for Kyverna Therapeutics tho, so...take that how you will)

www.thelancet.com/journals/lan...
December 14, 2023 at 5:29 PM
oncoassist.bsky.social
🚨 Latest #FDA Approval Update!

🔷 The FDA has approved a label update for Kite Pharma’s Yescarta® (axicabtagene ciloleucel), expanding its indication to include adults with relapsed or refractory primary central nervous system (CNS) lymphoma.
February 9, 2026 at 11:15 AM
jyves94.bsky.social
→ La catégorie la plus importante est celle des maladies #Hématologiques 🩸, qui couvrent des maladies comme le #Lymphome, le #MyélomeMultiple et l’ #Hémophilie

→ l’oncologie est la suivante, dirigée par les #ThérapiesCellulaires #CAR_T 🧬 comme #Kymriah, #Yescarta et #Breyanzi
November 6, 2025 at 5:46 AM
healthinsights.bsky.social
Gene Therapy Market Size to Surpass USD 3,251.92 Million by www.globenewswire.com/en/news-rele...
Gene Therapy Market Size to Surpass USD 3,251.92 Million by 2030 at 19.10% CAGR – Report by Market Research Future (MRFR)
Gene Therapy Market Trends and Insights By Product (Kymriah, Luxturna, Yescarta, Zolgensma, Strimvelis, Zynteglo), Indication (Oncology, Genetic Diseases)...
www.globenewswire.com
December 19, 2025 at 12:40 PM
sababausa.bsky.social
Yescarta requires intensive pre-treatment, harvesting and genetically modifying a population of the patient's cells, and costs ~€350,000 per treatment, so for now this approach if it works (authors can't discount that the pre-treatment chemo is what did it) would be indicated for highly severe cases
December 14, 2023 at 5:34 PM
jyves94.bsky.social
La thérapie #CAR_T 🧬 expérimentale #JNJ_4496 de #JohnsonAndJohnson a déclenché une réponse au traitement chez 100 % des patients atteints d’un #Lymphome 🩸 à grandes cellules B, ce qui pose un défi à la norme de soins actuelle de #Gilead, #Yescarta
#CAR_Tcells
www.biospace.com/drug-develop...
J&J’s Dual-Targeting CAR T Hits 80% Complete Response in Early Lymphoma Study
Analysts at Truist Securities called J&J’s CAR T readout “compelling,” noting that the efficacy figures could position the cell therapy as a formidable competitor to the current standard of care, Gile...
www.biospace.com
July 6, 2025 at 3:51 AM
paulwalker44.bsky.social
Some examples of the cost of specific cancer treatments include: • Atezolizumab (Tecentriq): Costs nearly $14,000 per month for lung, bladder, and liver cancer • Erdafitinib (Balversa): Costs between $10,000 and $22,000 per month for bladder cancer • Polatuzumab vedotin-piiq (Polivy): Costs $90,000 for a four-month course for a type of non-Hodgkin lymphoma • Yescarta: Costs $373,000 for one dose for the treatment of non-Hodgkin lymphoma • Kymriah: Costs $475,000 for one treatment course for acute lymphoblastic leukemia
September 15, 2024 at 2:42 PM
alexander-a-tin.bsky.social
Now from FDA, after probe last year into CAR T cell cancer treatments

Labels to add new warnings for Bristol Myers Squibb's Abecma/Breyanzi, Janssen's Carvykti, Novartis' Kymriah, Kite's Tecartus/Yescarta

"can increase your risk of getting cancers"

www.fda.gov/media/175623...
A screenshot of text that reads in part: ": 1. Boxed Warning, Highlights Section of the Prescribing Information (Pl) T cell malignancies have occurred following treatment with BCMA- and CD19- directed genetically modified autologous T cell immunotherapies, including ABECMA. (5.9) 2. Boxed Warning, Full Prescribing Information T cell malignancies have occurred following treatment with BCMA- and CD19- directed genetically modified autologous T cell immunotherapies, including ABECMA [see WARNINGS AND PRECAUTIONS (5.9)]. 3. WARNINGS AND PRECAUTIONS, Secondary Malignancies, Highlights Section of the PI Secondary malignancies: T cell malignancies have occurred following treatment with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including ABECMA. (5.9) 4. WARNINGS AND PRECAUTIONS, 5.9 Secondary Malignancies, Full Prescribing Information T cell malignancies have occurred following treatment with BCMA- and CD19- directed genetically modified autologous T cell
January 22, 2024 at 11:04 PM
sprintome.bsky.social
More info: https://www.fiercebiotech.com/research/study-yescarta-patients-reveals-genetic-red-flags-car-t-therapy-side-effects

#JoinTheSprint
sprintome.com
July 26, 2026 at 8:03 PM
sprintome.bsky.social
New analysis of Yescarta patients in clinical trials identifies genetic markers linked to therapy side effects. Insights could guide development of safer CAR-T treatments. Study sheds light on potential risk factors, aiding future therapy design.
July 26, 2026 at 8:03 PM
sprintome.bsky.social
More info: https://www.fiercebiotech.com/research/study-yescarta-patients-reveals-genetic-red-flags-car-t-therapy-side-effects

#JoinTheSprint
sprintome.com
July 25, 2026 at 1:04 PM
sprintome.bsky.social
New analysis of Kite Pharma's Yescarta trial patients identifies genetic red flags for CAR-T therapy side effects. Insights could lead to safer CAR-T designs. Promising development in treatment safety protocols.
July 25, 2026 at 1:04 PM
ceceliacare.bsky.social
"Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market"

#Caregiving #Healthcare #ElderCare #MedSky
Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market
With Yescarta joining the Korean CAR-T therapy market, already dominated by Kymriah, competition is expected to intensify. Industry attention is focused on the moves of Curocell, which is showing the fastest development speed among Korean companies.Curocell aims to secure market leadership by levera
www.koreabiomed.com
August 22, 2025 at 4:51 PM
ceceliacare.bsky.social
"Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market"

#Caregiving #Healthcare #ElderCare #MedSky
Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market
With Yescarta joining the Korean CAR-T therapy market, already dominated by Kymriah, competition is expected to intensify. Industry attention is focused on the moves of Curocell, which is showing the fastest development speed among Korean companies.Curocell aims to secure market leadership by levera
www.koreabiomed.com
August 22, 2025 at 4:51 PM
ceceliacare.bsky.social
"Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market"

#Caregiving #Healthcare #ElderCare #MedSky
Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market
With Yescarta joining the Korean CAR-T therapy market, already dominated by Kymriah, competition is expected to intensify. Industry attention is focused on the moves of Curocell, which is showing the fastest development speed among Korean companies.Curocell aims to secure market leadership by levera
www.koreabiomed.com
August 22, 2025 at 4:51 PM
ceceliacare.bsky.social
"Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market"

#Caregiving #Healthcare #ElderCare #MedSky
Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market
With Yescarta joining the Korean CAR-T therapy market, already dominated by Kymriah, competition is expected to intensify. Industry attention is focused on the moves of Curocell, which is showing the fastest development speed among Korean companies.Curocell aims to secure market leadership by levera
www.koreabiomed.com
August 22, 2025 at 4:51 PM
ceceliacare.bsky.social
"Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market"

#Caregiving #Healthcare #ElderCare #MedSky
Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market
With Yescarta joining the Korean CAR-T therapy market, already dominated by Kymriah, competition is expected to intensify. Industry attention is focused on the moves of Curocell, which is showing the fastest development speed among Korean companies.Curocell aims to secure market leadership by levera
www.koreabiomed.com
August 22, 2025 at 4:51 PM
ceceliacare.bsky.social
"Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market"

#Caregiving #Healthcare #ElderCare #MedSky
Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market
With Yescarta joining the Korean CAR-T therapy market, already dominated by Kymriah, competition is expected to intensify. Industry attention is focused on the moves of Curocell, which is showing the fastest development speed among Korean companies.Curocell aims to secure market leadership by levera
www.koreabiomed.com
August 22, 2025 at 4:50 PM
ceceliacare.bsky.social
"Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market"

#Caregiving #Healthcare #ElderCare #MedSky
Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market
With Yescarta joining the Korean CAR-T therapy market, already dominated by Kymriah, competition is expected to intensify. Industry attention is focused on the moves of Curocell, which is showing the fastest development speed among Korean companies.Curocell aims to secure market leadership by levera
www.koreabiomed.com
August 22, 2025 at 4:50 PM
ceceliacare.bsky.social
"Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market"

#Caregiving #Healthcare #ElderCare #MedSky
Curocell races to secure Korean CAR-T foothold as Yescarta joins Kymriah-dominated market
With Yescarta joining the Korean CAR-T therapy market, already dominated by Kymriah, competition is expected to intensify. Industry attention is focused on the moves of Curocell, which is showing the fastest development speed among Korean companies.Curocell aims to secure market leadership by levera
www.koreabiomed.com
August 22, 2025 at 4:49 PM